FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387142382> ?p ?o ?g. }

• W4387142382 abstract "<h3>Introduction/Background</h3> Pathogenic germline BRCA1 and BRCA2 (BRCA) variants are frequent in high-grade serous ovarian cancer (HGSOC). Age, tumor stage, and residual disease are known predictors of survival. However, it is not clear whether these associations differ by BRCA variant status. We examined the association between clinicopathological features and survival by BRCA status, in a large cohort of HGSOC patients. <h3>Methodology</h3> We evaluated clinicopathological and germline DNA sequencing data on 1,405 patients with HGSOC from 17 Australian treatment centres, enrolled into the Australian Ovarian Cancer Study between 2002–2023. Multivariate Cox proportional hazards models and logistic regression analysis were used to assess the association between prognostic factors and outcomes by BRCA status. <h3>Results</h3> The study population consisted of 1,112 (79.1%) non-carriers and 293 (20.9%) BRCA mutation carriers. Age, FIGO stage, BRCA status, primary site and residual disease showed a significant association with survival after risk factor adjustment. Non-carriers with residual disease showed a poorer overall survival compared to non-carriers with no residual disease (p<0.001, HR: 2.10, 95%CI: 1.75–2.50), whereas there was no significant difference in survival for patients with BRCA germline alterations with or without residual disease (p=0.188 and 0.221, HR: 1.17 and 0.8, 95%CI: 0.91–1.50 and 0.57–1.10, respectively). Patients with primary peritoneal carcinoma had a poorer survival than those with primary ovarian HGSOC (p=0.002, HR:1.33, 95%CI: 1.11–1.60). Patients with protein-truncating BRCA mutations had a better survival than those with splice-site, missense or structural variants (p<0.001). The results of the logistic regression analysis model aligned with the multivariate cox regression model. <h3>Conclusion</h3> Our results suggest that the adverse effect of residual disease is stronger for non-carriers compared to patients with a germline BRCA mutation. Thus, while optimal debulking improves outcomes for all patients with HGSOC, it may be particularly important to achieve no residual disease for non-carriers. <h3>Disclosures</h3> David D.L. Bowtell reports research support grants from AstraZeneca, Roche-Genentech and BeiGene outside the submitted work; also personal consulting fees from Exo Therapeutics, that are outside the submitted work. Anna DeFazio reports support grants and personal consulting fees from AstraZeneca outside the submitted work. All other authors declare that they have no conflicts of interest." @default.
• W4387142382 created "2023-09-29" @default.
• W4387142382 creator A5000030462 @default.
• W4387142382 creator A5014184022 @default.
• W4387142382 creator A5018531736 @default.
• W4387142382 creator A5023643377 @default.
• W4387142382 creator A5057552010 @default.
• W4387142382 creator A5063379605 @default.
• W4387142382 creator A5076400607 @default.
• W4387142382 creator A5078379854 @default.
• W4387142382 creator A5091883385 @default.
• W4387142382 date "2023-09-01" @default.
• W4387142382 modified "2023-09-29" @default.
• W4387142382 title "#70 Influence of predictive features on therapy response and survival in high-grade serous ovarian cancer patients by germline BRCA mutation status: an update from the australian ovarian cancer study" @default.
• W4387142382 doi "https://doi.org/10.1136/ijgc-2023-esgo.56" @default.
• W4387142382 hasPublicationYear "2023" @default.
• W4387142382 type Work @default.
• W4387142382 citedByCount "0" @default.
• W4387142382 crossrefType "proceedings-article" @default.
• W4387142382 hasAuthorship W4387142382A5000030462 @default.
• W4387142382 hasAuthorship W4387142382A5014184022 @default.
• W4387142382 hasAuthorship W4387142382A5018531736 @default.
• W4387142382 hasAuthorship W4387142382A5023643377 @default.
• W4387142382 hasAuthorship W4387142382A5057552010 @default.
• W4387142382 hasAuthorship W4387142382A5063379605 @default.
• W4387142382 hasAuthorship W4387142382A5076400607 @default.
• W4387142382 hasAuthorship W4387142382A5078379854 @default.
• W4387142382 hasAuthorship W4387142382A5091883385 @default.
• W4387142382 hasBestOaLocation W43871423821 @default.
• W4387142382 hasConcept C104317684 @default.
• W4387142382 hasConcept C109825262 @default.
• W4387142382 hasConcept C121608353 @default.
• W4387142382 hasConcept C126322002 @default.
• W4387142382 hasConcept C143998085 @default.
• W4387142382 hasConcept C150173356 @default.
• W4387142382 hasConcept C2777632260 @default.
• W4387142382 hasConcept C2780194787 @default.
• W4387142382 hasConcept C2780427987 @default.
• W4387142382 hasConcept C2908647359 @default.
• W4387142382 hasConcept C29456083 @default.
• W4387142382 hasConcept C3019054536 @default.
• W4387142382 hasConcept C50382708 @default.
• W4387142382 hasConcept C54355233 @default.
• W4387142382 hasConcept C71924100 @default.
• W4387142382 hasConcept C86803240 @default.
• W4387142382 hasConcept C99454951 @default.
• W4387142382 hasConceptScore W4387142382C104317684 @default.
• W4387142382 hasConceptScore W4387142382C109825262 @default.
• W4387142382 hasConceptScore W4387142382C121608353 @default.
• W4387142382 hasConceptScore W4387142382C126322002 @default.
• W4387142382 hasConceptScore W4387142382C143998085 @default.
• W4387142382 hasConceptScore W4387142382C150173356 @default.
• W4387142382 hasConceptScore W4387142382C2777632260 @default.
• W4387142382 hasConceptScore W4387142382C2780194787 @default.
• W4387142382 hasConceptScore W4387142382C2780427987 @default.
• W4387142382 hasConceptScore W4387142382C2908647359 @default.
• W4387142382 hasConceptScore W4387142382C29456083 @default.
• W4387142382 hasConceptScore W4387142382C3019054536 @default.
• W4387142382 hasConceptScore W4387142382C50382708 @default.
• W4387142382 hasConceptScore W4387142382C54355233 @default.
• W4387142382 hasConceptScore W4387142382C71924100 @default.
• W4387142382 hasConceptScore W4387142382C86803240 @default.
• W4387142382 hasConceptScore W4387142382C99454951 @default.
• W4387142382 hasLocation W43871423821 @default.
• W4387142382 hasOpenAccess W4387142382 @default.
• W4387142382 hasPrimaryLocation W43871423821 @default.
• W4387142382 hasRelatedWork W1983813901 @default.
• W4387142382 hasRelatedWork W2004144597 @default.
• W4387142382 hasRelatedWork W2019814960 @default.
• W4387142382 hasRelatedWork W2112481692 @default.
• W4387142382 hasRelatedWork W2116186978 @default.
• W4387142382 hasRelatedWork W2805900528 @default.
• W4387142382 hasRelatedWork W2973321127 @default.
• W4387142382 hasRelatedWork W3210326642 @default.
• W4387142382 hasRelatedWork W4321788541 @default.
• W4387142382 hasRelatedWork W4385380379 @default.
• W4387142382 isParatext "false" @default.
• W4387142382 isRetracted "false" @default.
• W4387142382 workType "article" @default.